PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Conditions: Metastatic Castration-Resistant Prostate Cancer

First Posted Date: 2022-12-14

Last Posted Date: 2023-11-15

Lead Sponsor: Pfizer

Registration Number: NCT05650476

A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

Completed

Conditions: Thromboembolism

First Posted Date: 2022-12-09

Last Posted Date: 2024-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 10000

Registration Number: NCT05643885

Locations: 🇺🇸
Pfizer Investigational, New York, New York, United States

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Phase 2

Recruiting

Conditions: Gram-negative Bacterial Infections

Interventions: Drug: ATM-AVI
Drug: BAT

First Posted Date: 2022-12-06

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT05639647

Locations: 🇹🇷
Cukurova Universty, Sarçam, Adana, Turkey
🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸
Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York, United States

and more 29 locations

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Phase 3

Active, not recruiting

Conditions: Lyme Disease

Interventions: Other: Normal Saline
Biological: VLA15

First Posted Date: 2022-12-02

Last Posted Date: 2025-03-14

Lead Sponsor: Pfizer

Target Recruit Count: 3235

Registration Number: NCT05634811

Locations: 🇺🇸
Velocity Clinical Research, Vestal, Vestal, New York, United States
🇺🇸
UAB Child Health Research Unit (CHRU), Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States

and more 62 locations

Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi

Phase 4

Active, not recruiting

Conditions: Invasive Fungal Disease

Interventions: Drug: Isavuconazole

First Posted Date: 2022-11-30

Last Posted Date: 2025-02-05

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT05630976

Locations: 🇨🇳
Zibo Central Hospital, Zibo, Shandong, China
🇨🇳
The First Affiliated Hospital of USTC, Anhui Province Hospital, Hefei, Anhui, China
🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 11 locations

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

Phase 2

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Osivelotor

First Posted Date: 2022-11-30

Last Posted Date: 2025-04-20

Lead Sponsor: Pfizer

Target Recruit Count: 47

Registration Number: NCT05632354

Locations: 🇺🇸
Our Lady of the Lake Hospital, Inc., Baton Rouge, Louisiana, United States
🇺🇸
University Medical Center New Orleans, New Orleans, Louisiana, United States
🇺🇸
Mississippi Center for Advanced Medicine, Madison, Mississippi, United States

and more 5 locations

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Maplirpacept
Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2022-11-23

Last Posted Date: 2025-02-13

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT05626322

Locations: 🇺🇸
Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States

and more 4 locations

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Daratumumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2022-11-21

Last Posted Date: 2025-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 1116

Registration Number: NCT05623020

Locations: 🇪🇸
Clinica Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸
Hospital San Pedro de Alcántara, Cáceres, Spain
🇪🇸
Hospital La Princesa, Madrid, Spain

and more 61 locations

A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People

Completed

Conditions: COVID-19

Interventions: Biological: BNT162b2

First Posted Date: 2022-11-17

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 260

Registration Number: NCT05621239

Locations: 🇮🇩
Pfizer, Jakarta, Indonesia

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

Phase 3

Recruiting

Conditions: Hemophilia A
Hemophilia B

Interventions: Drug: marstacimab

First Posted Date: 2022-11-10

Last Posted Date: 2024-12-24

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT05611801

Locations: 🇺🇸
Intermountain - Primary Children's Hospital, Salt Lake City, Utah, United States
🇦🇷
Arbesu Hematología, Mendoza, Argentina
🇦🇺
Sydney Children's Hospital, Randwick, New South Wales, Australia

and more 61 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy